Uncategorized

Regeneron reaches $125M Parabilis deal for hard-to-catch drug targets

Regeneron reaches $125M Parabilis deal for hard-to-catch drug targets

Published

4 weeks ago

on

As Regeneron’s cancer portfolio continues to suffer setbacks, the company is placing a bet in a different direction through a deal with Parabilis Medicines valued at as much as $2.2 billion.

Parabilis is focused on …​ ​Read More

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version